Monsenso to participate in AI-enabled personalised mental health therapy project

Monsenso to participate in AI-enabled personalised mental health therapy project

Dec 13, 2022

Monsenso and a consortium of partners have received a grant letter from a funding entity to develop and trial a new, AI-enabled personalised therapy concept for people with mental disorders.

Currently, digital mental health interventions are largely developed as a one-size-fits-all approach, where patients get a fixed 6-12 week intervention and where drop-out rates are relatively high.

With the grant letter received, Monsenso is entering grant agreement negotiations with a consortium of leading researchers in clinical psychology, internet-based therapy, health economics and AI to develop and trial a new AI-enabled personalised care concept based on Monsenso’s platform. The four-year project is anticipated to start in Q2-2023 and is expected to contribute with DKK 3.9 mio to Monsenso.

“With this project, we will further develop our platform’s ability to deliver personalised digital treatment programs and to ensure optimal adherence to treatment. By leveraging patients’ own data and artificial intelligence, the aim is to be able to give more engaging and personalised care based on patients’ actual state, so that patients are offered the right treatment at the right time in a scalable way”, says Thomas Lethenborg, CEO of Monsenso.

Full disclosure of the project details including consortium members, funding program, and disorder area will be possible upon signature of the grant agreement, which is expected in Q1 of 2023.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

BOOK A DEMO
Monsenso releases enhanced version of its clinical web portal & refreshed patient app

Monsenso releases enhanced version of its clinical web portal & refreshed patient app

Dec 1, 2022

Monsenso releases an enhanced version of its clinical web portal and a refreshed patient app. The product enhancements entail an improved and even more intuitive user interface of the solution’s patient app and clinical web portal in order to enhance remote patient monitoring and treatment support for clinicians, as well as the communication and collaboration between clinician and patient.

Among others, the enhancements allow clinicians to recommend treatment content to the patients individually to support personalised treatment. Clinicians can now recommend their patients to do specific exercises, visit the library with psychoeducational content or answer a specific clinical questionnaire. Once the clinician has made a recommendation via the clinical web portal, patients are notified and it is immediately emphasised in the patient’s app. This allows clinicians to provide more personalised treatment and also helps engage and empower patients in taking care of their own mental health.

The product enhancements result from an extensive, user-centered design process involving patients and clinicians in both design and testing phases to ensure the enhancements meet the needs of our users.

“We are excited to offer an improved version of our digital health solution to partners, clients, and patients. The feedback we have received during extensive internal and external testing periods has been excellent, and we are looking forward to empowering individuals, their carers, and clinicians even more on the treatment pathway”, says CEO, Thomas Lethenborg.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

BOOK A DEMO
Monsenso signs contract with private Danish psychiatric clinic Appia Klinikken in Søborg

Monsenso signs contract with private Danish psychiatric clinic Appia Klinikken in Søborg

Dec 1, 2022

Monsenso signs a contract with the private Danish psychiatric clinic Appia Klinikken in Søborg, Zealand. The Monsenso digital health solution will be implemented at the beginning of 2023 and will be used to support patients and clinicians at the clinic.

Appia Klinikken is a Danish specialist psychiatric clinic offering treatment and support to individuals suffering from mental illness. Though the clinic has a focus on child and adolescent mental health, it offers treatment to individuals of all age groups.

The team of psychologists and psychiatrists at Appia Klinikken is led by specialist psychiatrist Mie Bonde, who “is professionally recognized for her holistic approach and for her work with clients with ADHD and/or ASD diagnoses, as well as clients with abuse combined with diagnosis(es)” [1].

The Monsenso solution will be used at Appia Klinikken for two different purposes. Primarily, the Monsenso solution will be used to screen patients while they are waiting for treatment and to monitor them during treatment. Secondly, the Monsenso solution will be used to collect data for effect documentation of a newly established type of treatment called “hypnotherapy” and for use of medication.

Specialist psychiatrist Mie Bonde says: “The Monsenso digital health solution will not only enable us to support patients more actively during treatment, but also to give patients information on how to reduce stress while they are still waiting to receive treatment. Waiting lists are something we cannot avoid entirely, but tools like the Monsenso solution enable us to make them more proactive”.
——————————————————————————————————————————-
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com.

References:
[1] Appia Klinikken (n.d.). Appia Klinikken – Vejenes dronning.
https://www.appia-klinikken.dk/

BOOK A DEMO
The Momentum Trial: How digital tools can support patient-centered care & shared decision-making

The Momentum Trial: How digital tools can support patient-centered care & shared decision-making

Nov 10, 2022

In the delivery of mental health services, shared decision-making (SDM) is increasingly becoming more important [1]. SDM can be defined as a collaborative process between patient and health care provider, enabling joint treatment decisions and patient-centered care [2]. Research suggests that in mental healthcare, SDM could “contribute to recovery-oriented care by inviting the patient to have more control and be more involved in their treatment decisions” [2]. 

However, many mental health care providers are still reluctant to incorporate SDM into their treatment offers, as they believe it to be unfit for individuals suffering from severe mental illness, as well as to be time-consuming and thus a burden [3,4]. To overcome these challenges of incorporating SDM into daily practices, healthcare professionals have been encouraged to utilize “tools to support the SDM process” [2]. 

Increased focus has thus been placed on how digital interventions could support SDM in mental healthcare [2]. The Momentum Trial is a study investigating how using a smartphone app as a support tool could help “individuals suffering from schizophrenia-spectrum disorders in an outpatient treatment setting” [5]. 

During the trial, 194 participants were randomized either to receive “specialized early intervention treatment with the Momentum app” (intervention group) or to receive regular treatment without a smartphone app (control group) [5]. The Monsenso digital health solution, consisting of a patient app and a clinical web portal, was used for the intervention group. The Monsenso solution provided tools such as psychoeducational material, daily self-assessments, and action plans in the patient app, as well as patient insights in the clinical web portal [2].

As a primary outcome, it was investigated whether the individuals from the two groups would show a difference in self-perceived patient activation. Patient activation can play an important role in successful SDM processes, as patients who are more active and engaged in their treatment “feel confident when collaborating with their provider, and have the knowledge and skills to manage their condition” [2]. 

As secondary outcomes, it was investigated whether the individuals from the two different groups would show a difference in the self-perceived feeling of hope and optimism, self-efficacy, confidence in communicating with their provider, therapeutic alliance between the patient and provider, feeling prepared to make a treatment decision, and satisfaction with treatment [2]. 

Results were evaluated at baseline, as well as 3 and 6 months post-baseline. Promisingly, the Momentum Trial showed a significant effect of a digital SDM tool on the subjective level of patient activation, confidence in communicating with one’s provider, and feeling prepared for decision-making at the postintervention time point [2]. 

Though no statistically significant effects could be found related to the digital SDM intervention’s effect on working alliance, treatment satisfaction, clinical outcomes, and hope, the results from the Momentum Trial “confirm [the] hypothesis that a digital SDM tool may promote patient activation by supporting the collaborative process between patients and their providers” [2]

Monsenso CEO Thomas Lethenborg says: “The Momentum Trial shows how promising digital tools are in supporting shared decision-making. At Monsenso, we are proud to have been involved in this research project, and look forward to empowering individuals and clinicians even more on the treatment pathway”.
——————————————————————————————————————————-

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and health care providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com

References:
[1] Alguera-Lara, V., Dowsey, M., Ride, J., Kinder, S. & Castle, D. (2017). Shared decision making in mental health: the importance for current clinical practice. Australas Psychiatry, 25(6), 578-582. 

[2] Vitger, T., Hjorthøj, C., Austin, S.F., Petersen, L., Tønder, E.S., Nordentoft, M. & Korsbek, L. (2022). A Smartphone App to Promote Patient Activation and Support Shared Decision-making in People With a Diagnosis of Schizophrenia in Outpatient Treatment Settings (Momentum Trial): Randomized Controlled Assessor-Blinded Trial. Journal of Medical Internet Research, 24(10), e40292.
https://www.jmir.org/2022/10/e40292

[3] Hamann, J. & Heres, S. (2014). Adapting shared decision making for individuals with severe mental illness. Psychiatric Services, 65(12), 1483-1486.
https://ps.psychiatryonline.org/doi/full/10.1176/appi.ps.201400307

[4] Waldemar, A.K., Esbensen, B.A., Korsbek, L., Petersen, L. & Arnfred, S (2019). Recovery-oriented practice: participant observations of the interactions between patients and health professionals in mental health inpatient settings. International Journal of Mental Health Nursing, 28(1), 318-329. https://onlinelibrary.wiley.com/doi/10.1111/inm.12537

[5] Korsbek, L. (n.d.). The Momentum Trial: The efficacy of using a smartphone application to support shared decision making for people with a diagnosis of schizophrenia in an outpatient treatment setting. Open Patient data Explorative Network.
https://open.rsyd.dk/OpenProjects/openProject.jsp?openNo=451&lang=da

​​

BOOK A DEMO
DIPNOT: A Research Project to Improve Psychotherapeutic Treatment for People with Depression

DIPNOT: A Research Project to Improve Psychotherapeutic Treatment for People with Depression

Oct 25, 2022

Monsenso is proud to be part of the Development of an Intervention for Persistent Not On Track (DIPNOT) research project that aims to improve psychotherapeutic treatment offered to people with depression in psychiatry.

Though often said to be one of the “happiest countries on earth”, depression is no rare illness in Denmark. Did you know, that approximately 15-25% of all females and 7-12% of all males living in Denmark experience depression at least once in their life? [1].

After diagnosis, patients with depression are often offered group-based cognitive behavioural therapy (CBT) in outpatient psychiatry in Denmark [2]. However, around 50% of depressed patients participating in group-based CBT do not actually feel their symptoms improving, or even worsening during the therapy [2].

The DIPNOT research project, which was started in 2021 and continues until 2024, hence aims to design an intervention for patients with depression who are not improving during the course of their therapy. The idea is to monitor patients and the progression of their symptoms via a digital health application (e.g., using clinical questionnaires) and identify the patients who are not doing well during the therapy [2].

The Monsenso digital health solution is currently being used for this purpose in the DIPNOT project conducted by ph.d. student Jasmin Rejaye Gryesten. It facilitates the identification of worsening depressive symptoms and offers various possibilities for clinicians to provide their patients with digital tools that can help their recoveries – such as exercises and psychoeducational content.

At Monsenso, we are proud to be part of this exciting journey toward offering better mental health to more people by being able to cater to patients’ needs more individually.

If you want to learn more about the DIPNOT project, watch this video!
——————————————————————————————————————————-

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com

References:
[1] Kessing, L.V. (2021). ​​Depression, forekomst. Sundhed.dk.
https://www.sundhed.dk/borger/patienthaandbogen/psyke/sygdomme/depression/depression-forekomst/

[2] DIPNOT (n.d.). Development of an Intervention for Persistent Not On Track.
https://www.dipnot.dk

​​

BOOK A DEMO
Patients will help document treatment efficacy in innovative, decentralised trials project

Patients will help document treatment efficacy in innovative, decentralised trials project

Sep 28, 2022

In collaboration with leading researchers and the pharmaceutical industry, the PhaseV innovation project will set new standards for how the effects of treatment can be documented so that patients are offered the right treatment. Patients and healthcare professionals will thus provide data that can help shed light on whether the treatment is working when Monsenso’s digital platform is used to support decentralised trials in the project.

To date, medical treatments have been tested primarily in long-term, randomised clinical trials to determine treatment effects and side-effects, with limited measurement of long-term effects when treatment is provided in clinical practice.

Often, drug trials take 6-15 years before a new drug can be released on the market, and 80 percent of trials fail to recruit and retain a sufficient number of patients in the trials within the set timeframe. This means that the benefits for patients and healthcare systems are often delayed. However, with digital developments, it is possible for clinics, hospitals, and patients alike to play a more active role in documenting the impact of treatments.

The new PhaseV (Phase five) innovation project, in which Innovation Fund Denmark is investing DKK 24 million (of which DKK 8,3 million goes to Monsenso), aims to develop and validate a scalable digital platform for efficient, decentralised patient recruitment, patient data collection and study execution. This is done by engaging patients and clinicians in the monitoring of treatment effects over longer periods of time based on patients’ own feedback, digital biomarkers from smartphones and wearables, as well as registry data.

“With this project, we want to show that it is possible to engage and motivate patients and healthcare professionals to collect continuous data from patients over time. PhaseV will set new standards for how the efficacy and safety of new treatments can be documented in a scalable way in the future, so that patients are offered the right treatment“, says Thomas Lethenborg, CEO of Monsenso.

“Digitizing the effect of patient treatments can be of decisive importance for our insight into the effects of the treatment of severely overweight people as well as for future clinical studies, where the goal is to make it easier for both patients and healthcare personnel to participate“, says Daniel Vega Møller, Vice President Medical & Science Obesity, NASH and Devices Novo Nordisk A/S.

Country Manager for Novartis in Denmark, Peter Drøidal, also sees great potential in the PhaseV project: “The healthcare system lacks resources and therefore we all need to think in new ways. This project’s combination of public and private partners offers unique opportunities to develop new digital solutions that can help improve patient care and free up personnel time“.

Severe obesity, urticaria and diabetic foot ulcers
The PhaseV project will develop a platform with three apps to collect data on patients with severe obesity, diabetic foot ulcers and urticaria – all of which are costly chronic conditions. For example, annual treatment costs for severe obesity alone are estimated to exceed DKK 15 billion for Danish municipalities and regions.

“More than 800,000 Danes live with severe obesity, and associated diseases are very common. As severe obesity causes both direct and indirect costs to society, there is a significant need for good and well-documented weight loss treatments“, says Jens Meldgaard Bruun, clinical professor at Aarhus University and Steno Diabetes Center Aarhus and part of PhaseV.

Urticaria affects 15-20 percent of the population, and in about 1 percent it occurs chronically and causes a severely reduced quality of life.

“Thorough monitoring and efficient data collection on symptom development are crucial for correct and effective future treatment“, says Simon Francis Thomsen, Professor and Chief Physician at Bispebjerg Hospital.

22.000 Danes live with diabetic foot ulcers and treatment costs society more than DKK 5 billion annually.

“For a patient with diabetes, a foot ulcer can become critical within days, and in exceptional cases amputation may be necessary. Hence, time is of the essence, and we want to prevent serious complications“, says Klaus Kirketerp-Møller, senior physician at Bispebjerg Hospital and Steno Diabetes Center Copenhagen.

The PhaseV project is expected to bring value to patients, regions, and municipalities, as well as to the institutions and companies involved.

Attractive new market opportunity for Monsenso
“We are further developing Monsenso’s digital health platform to improve the support of decentralised trials across chronic conditions, where behaviour and ongoing follow-up play a major role in patients’ quality of life. We see both the development work and the partnerships as very interesting for Monsenso, because it opens up a new, attractive market opportunity“, says the CEO of Monsenso, Thomas Lethenborg.

The consortium behind the project, which is supported by the Innovation Fund, includes Novo Nordisk, Novartis, Aarhus University, the Research Unit for General Practice, Aarhus Municipality, Bispebjerg Hospital, the Danish Technological Institute, the Danish Life Science Cluster, Steno Diabetes Center Aarhus, the Copenhagen Institute for Future Studies and Monsenso.

Financial expectations
The project does not change Monsenso’s financial expectations for H2 2022 but is expected to contribute to increased growth in 2023 and beyond.

Facts
Innovation Fund investment: DKK 24.3 million (of which DKK 8.3 million is for Monsenso).
Total project budget: DKK 48.2 million.
Duration: 3 years
Official title: PhaseV

Further information
CEO, Monsenso
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com

Chairman of the board, Monsenso
Peter Mørch Eriksen
Tel. +45 29 00 35
E-mail: petermorcheriksen@outlook.com

Certified Adviser, Monsenso
Norden CEF A/S
John Norden
Tel. +45 20 72 02 00
E-mail: jn@nordencef.dk
——————————————————————————————————————————-

About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com

 
BOOK A DEMO